Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-511X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin ; volume:10 ; number:1 ; day:16 ; month:11 ; year:2011 ; pages:1-9 ; date:12.2011
Lipids in health and disease ; 10, Heft 1 (16.11.2011), 1-9, 12.2011
- Urheber
-
Farnier, Michel
Dong, Qian
Shah, Arvind
Johnson-Levonas, Amy O.
Brudi, Philippe
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/1476-511X-10-212
- URN
-
urn:nbn:de:101:1-2019062701302713868248
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Farnier, Michel
- Dong, Qian
- Shah, Arvind
- Johnson-Levonas, Amy O.
- Brudi, Philippe
- SpringerLink (Online service)
Ähnliche Objekte (12)
Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes
Assessment of femoral bone osteoporosis in rats treated with simvastatin or fenofibrate
Enhanced therapeutic efficacy of doxorubicin/cyclophosphamide in combination with pitavastatin or simvastatin against breast cancer cells
Pseudomyopia with paradoxical accommodation: a case report
Paradoxical
Lack of Pharmacokinetic Interactions Between Dapagliflozin and Simvastatin, Valsartan, Warfarin, or Digoxin
Individualizing simvastatin dose with respect to CYP3A4 activity
Higher non-HDL-cholesterol to HDL-cholesterol ratio linked with increased nonalcoholic steatohepatitis
Referenzwerte für Apolipoproteine und HDL-2/HDL-3 [HDL-HDL] im Kindesalter
Lower or higher HDL-C levels are associated with cardiovascular events in the general population in rural China
Differential association of ezetimibe-simvastatin combination with major adverse cardiovascular events in patients with or without diabetes: a retrospective propensity score-matched cohort study
Delay posttraumatic paradoxical cerebrospinal fluid leak with recurrent meningitis
Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes
Assessment of femoral bone osteoporosis in rats treated with simvastatin or fenofibrate
Enhanced therapeutic efficacy of doxorubicin/cyclophosphamide in combination with pitavastatin or simvastatin against breast cancer cells
Pseudomyopia with paradoxical accommodation: a case report
Paradoxical
Lack of Pharmacokinetic Interactions Between Dapagliflozin and Simvastatin, Valsartan, Warfarin, or Digoxin
Individualizing simvastatin dose with respect to CYP3A4 activity
Higher non-HDL-cholesterol to HDL-cholesterol ratio linked with increased nonalcoholic steatohepatitis
Referenzwerte für Apolipoproteine und HDL-2/HDL-3 [HDL-HDL] im Kindesalter
Lower or higher HDL-C levels are associated with cardiovascular events in the general population in rural China
Differential association of ezetimibe-simvastatin combination with major adverse cardiovascular events in patients with or without diabetes: a retrospective propensity score-matched cohort study
Delay posttraumatic paradoxical cerebrospinal fluid leak with recurrent meningitis
Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes
Assessment of femoral bone osteoporosis in rats treated with simvastatin or fenofibrate
Enhanced therapeutic efficacy of doxorubicin/cyclophosphamide in combination with pitavastatin or simvastatin against breast cancer cells
Pseudomyopia with paradoxical accommodation: a case report
Paradoxical
Lack of Pharmacokinetic Interactions Between Dapagliflozin and Simvastatin, Valsartan, Warfarin, or Digoxin
Individualizing simvastatin dose with respect to CYP3A4 activity
Higher non-HDL-cholesterol to HDL-cholesterol ratio linked with increased nonalcoholic steatohepatitis
Referenzwerte für Apolipoproteine und HDL-2/HDL-3 [HDL-HDL] im Kindesalter
Lower or higher HDL-C levels are associated with cardiovascular events in the general population in rural China
Differential association of ezetimibe-simvastatin combination with major adverse cardiovascular events in patients with or without diabetes: a retrospective propensity score-matched cohort study